271 related articles for article (PubMed ID: 24835528)
1. Remission of disseminated cancer after systemic oncolytic virotherapy.
Russell SJ; Federspiel MJ; Peng KW; Tong C; Dingli D; Morice WG; Lowe V; O'Connor MK; Kyle RA; Leung N; Buadi FK; Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A
Mayo Clin Proc; 2014 Jul; 89(7):926-33. PubMed ID: 24835528
[TBL] [Abstract][Full Text] [Related]
2. Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy.
Marchica V; Franceschi V; Vescovini R; Storti P; Vicario E; Toscani D; Zorzoli A; Airoldi I; Dalla Palma B; Campanini N; Martella E; Mancini C; Costa F; Donofrio G; Giuliani N
J Hematol Oncol; 2020 Jul; 13(1):89. PubMed ID: 32653014
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
[TBL] [Abstract][Full Text] [Related]
4. Taming measles virus to create an effective cancer therapeutic.
Bell JC
Mayo Clin Proc; 2014 Jul; 89(7):863-5. PubMed ID: 24835529
[No Abstract] [Full Text] [Related]
5. MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy.
Ruiz AJ; Hadac EM; Nace RA; Russell SJ
J Virol; 2016 Apr; 90(8):4078-4092. PubMed ID: 26865716
[TBL] [Abstract][Full Text] [Related]
6. Trial Watch:: Oncolytic viruses for cancer therapy.
Pol J; Bloy N; Obrist F; Eggermont A; Galon J; Cremer I; Erbs P; Limacher JM; Preville X; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014; 3():e28694. PubMed ID: 25097804
[TBL] [Abstract][Full Text] [Related]
7. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
Engeland CE; Grossardt C; Veinalde R; Bossow S; Lutz D; Kaufmann JK; Shevchenko I; Umansky V; Nettelbeck DM; Weichert W; Jäger D; von Kalle C; Ungerechts G
Mol Ther; 2014 Nov; 22(11):1949-59. PubMed ID: 25156126
[TBL] [Abstract][Full Text] [Related]
8. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.
Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Virotherapy: A Contest between Apples and Oranges.
Russell SJ; Peng KW
Mol Ther; 2017 May; 25(5):1107-1116. PubMed ID: 28392162
[TBL] [Abstract][Full Text] [Related]
11. Mayo breakthrough: virus may destroy bone marrow cancer.
Mayo Clin Health Lett; 2014 Sep; 32(9):4. PubMed ID: 25233543
[No Abstract] [Full Text] [Related]
12. Oncolytic polio virotherapy of cancer.
Brown MC; Dobrikova EY; Dobrikov MI; Walton RW; Gemberling SL; Nair SK; Desjardins A; Sampson JH; Friedman HS; Friedman AH; Tyler DS; Bigner DD; Gromeier M
Cancer; 2014 Nov; 120(21):3277-86. PubMed ID: 24939611
[TBL] [Abstract][Full Text] [Related]
13. Designing and building oncolytic viruses.
Maroun J; Muñoz-Alía M; Ammayappan A; Schulze A; Peng KW; Russell S
Future Virol; 2017 Apr; 12(4):193-213. PubMed ID: 29387140
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cells for sustained remissions in leukemia.
Maude SL; Frey N; Shaw PA; Aplenc R; Barrett DM; Bunin NJ; Chew A; Gonzalez VE; Zheng Z; Lacey SF; Mahnke YD; Melenhorst JJ; Rheingold SR; Shen A; Teachey DT; Levine BL; June CH; Porter DL; Grupp SA
N Engl J Med; 2014 Oct; 371(16):1507-17. PubMed ID: 25317870
[TBL] [Abstract][Full Text] [Related]
15. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
16. Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma.
Domingo-Musibay E; Allen C; Kurokawa C; Hardcastle JJ; Aderca I; Msaouel P; Bansal A; Jiang H; DeGrado TR; Galanis E
Cancer Gene Ther; 2014 Nov; 21(11):483-90. PubMed ID: 25394505
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viruses: a new class of immunotherapy drugs.
Kaufman HL; Kohlhapp FJ; Zloza A
Nat Rev Drug Discov; 2015 Sep; 14(9):642-62. PubMed ID: 26323545
[TBL] [Abstract][Full Text] [Related]
18. Going viral with cancer immunotherapy.
Lichty BD; Breitbach CJ; Stojdl DF; Bell JC
Nat Rev Cancer; 2014 Aug; 14(8):559-67. PubMed ID: 24990523
[TBL] [Abstract][Full Text] [Related]
19. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
20. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
Msaouel P; Opyrchal M; Dispenzieri A; Peng KW; Federspiel MJ; Russell SJ; Galanis E
Curr Cancer Drug Targets; 2018; 18(2):177-187. PubMed ID: 28228086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
